H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Protalix (PLX) to $12 from $15 and keeps a Buy rating on the shares following the Q3 report. The firm cites a more gradual ramp in Elfabrio sales and associated royalties for the target drop.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLX: